TRM6 Antibody

What is TRMT6 and what cellular functions does it perform?

TRMT6, also known as tRNA methyltransferase 6 homolog (S. cerevisiae) or GCD10, is a 497 amino acid nuclear protein that functions primarily in tRNA modification pathways. It exists as a heterodimer with TRMT61A (also known as TRM61) and serves as the substrate-binding subunit for tRNA methylation processes . The protein plays a critical role in regulating the efficiency of mRNA translation by helping maintain correct reading frames within mRNA through specific tRNA modifications .

Recent research has revealed that TRMT6 has significant functions in stem cell biology, particularly in hematopoietic stem cell (HSC) maintenance and self-renewal pathways. The protein appears to be part of the tRNA m1A modification system that regulates these critical stem cell processes . TRMT6 expression has been detected in multiple tissues, with notable expression in liver, brain, ovary and testis .

What are the key specifications of commercially available TRMT6 antibodies?

Commercial TRMT6 antibodies are available with various specifications depending on the manufacturer and intended applications. Based on available data, these antibodies typically have the following characteristics:

The antibodies are typically purified using Protein A purification methods and are supplied in liquid form . Always refer to the specific manufacturer's datasheet for the exact specifications of your antibody.

What types of samples have been successfully used with TRMT6 antibodies?

TRMT6 antibodies have demonstrated successful detection in various sample types across different applications:

For Western Blotting:

• Human cell lines: U-251, HepG2, U-87 MG, SMMC-7721, HuH-7

• Mouse tissue: Brain tissue

For Immunohistochemistry:

• Human tissue: Ovarian cancer tissue (with recommended antigen retrieval using TE buffer pH 9.0 or alternatively citrate buffer pH 6.0)

For Immunofluorescence/Immunocytochemistry:

• Human cell lines: A431 cells

This diversity of sample types indicates the versatility of TRMT6 antibodies for detecting the target protein across different species and experimental systems.

How can researchers optimize TRMT6 antibody use in various applications?

Optimization of TRMT6 antibody use requires application-specific considerations:

For Western Blotting:

• Recommended dilution range: 1:2000-1:16000

• Expected band size: 55-60 kDa

• Sample preparation: Standard cell/tissue lysis protocols are generally effective

For Immunohistochemistry:

• Recommended dilution range: 1:600-1:2400

• Antigen retrieval: TE buffer pH 9.0 is preferred; citrate buffer pH 6.0 is an alternative

• Detection system: Both chromogenic and fluorescent detection systems are compatible

For Immunofluorescence/Immunocytochemistry:

• Recommended dilution range: 1:200-1:800

• Fixation: Standard paraformaldehyde fixation (4%) is generally effective

• Permeabilization: Mild detergent treatment (0.1-0.5% Triton X-100)

It is strongly recommended to titrate the antibody in each testing system to determine optimal conditions for your specific experimental setup, as sample type and preparation method can significantly impact results.

What approaches can be used to study TRMT6-TRMT61A interactions in experimental systems?

Studying the TRMT6-TRMT61A heterodimer interaction requires specialized approaches:

• Co-immunoprecipitation (Co-IP): TRMT6 antibodies can be used to pull down the protein complex, followed by Western blotting for TRMT61A to confirm interaction. This approach requires careful optimization of lysis conditions to preserve protein-protein interactions.

• Proximity Ligation Assay (PLA): This technique can visualize protein interactions in situ using TRMT6 and TRMT61A antibodies raised in different host species, followed by species-specific secondary antibodies with attached oligonucleotides that generate fluorescent signals when in close proximity.

• FRET/BRET Analysis: When studying overexpressed tagged versions of these proteins, these techniques can provide quantitative data on protein interactions in living cells.

• Mass Spectrometry Analysis: Immunoprecipitation with TRMT6 antibodies followed by LC-MS/MS can identify interaction partners, as demonstrated in proteome-wide approaches similar to those used in the PETAL system .

The heterodimeric nature of the TRMT6-TRMT61A complex should be considered when designing experiments, as conditions that disrupt this interaction may affect antibody recognition or functional outcomes.

How can TRMT6 antibodies be used to investigate tRNA modification pathways in disease models?

TRMT6 antibodies can be valuable tools for investigating tRNA modification pathways in disease contexts:

• Expression Analysis: Changes in TRMT6 expression across disease states can be quantified using Western blotting and immunohistochemistry. This is particularly relevant in cancer models, where tRNA modifications may be dysregulated.

• Localization Studies: Immunofluorescence with TRMT6 antibodies can reveal changes in subcellular localization that may occur during disease progression.

• ChIP Assays: For investigating potential interactions between TRMT6 and chromatin, which may reveal novel regulatory mechanisms beyond direct tRNA modification.

• Functional Assays: Combining TRMT6 knockdown/knockout approaches with antibody-based detection to correlate protein levels with functional outcomes in tRNA modification assays.

Recent research on hematopoietic stem cells indicates that TRMT6 plays a role in HSC maintenance and self-renewal through tRNA m1A modification . This suggests TRMT6 antibodies could be particularly useful in studying hematological disorders and stem cell function.

What controls should be included when using TRMT6 antibodies in experiments?

Proper controls are essential for generating reliable data with TRMT6 antibodies:

Positive Controls:

• Known TRMT6-expressing cell lines: U-251, HepG2, U-87 MG, SMMC-7721, HuH-7 cells

• Tissue samples: Mouse brain tissue, human ovarian cancer tissue

Negative Controls:

• Primary Antibody Omission: Samples processed identically but without primary antibody

• Isotype Control: Non-specific rabbit IgG at the same concentration as the TRMT6 antibody

• TRMT6 Knockdown/Knockout: Genetically modified cells or tissues with reduced/absent TRMT6 expression

• Blocking Peptide: Pre-incubation of the antibody with a specific blocking peptide (similar to approaches used for other antibodies like TRPM6)

Loading/Staining Controls:

• Western blotting: Housekeeping proteins (β-actin, GAPDH, tubulin)

• Immunohistochemistry/Immunofluorescence: DAPI nuclear staining

These controls help distinguish specific from non-specific signals and validate the reliability of experimental findings.

What are the best practices for troubleshooting non-specific binding with TRMT6 antibodies?

When encountering non-specific binding with TRMT6 antibodies, consider the following troubleshooting approaches:

• Optimize Antibody Dilution: Test a range of dilutions, starting with the manufacturer's recommendation (1:2000-1:16000 for WB, 1:600-1:2400 for IHC, 1:200-1:800 for IF/ICC) .

• Improve Blocking: Increase blocking time or try alternative blocking agents (5% BSA, 5% non-fat dry milk, commercial blocking buffers).

• Increase Washing Stringency: Additional washes with higher detergent concentration (0.1-0.5% Tween-20) can reduce background.

• Optimize Sample Preparation:

  • For Western blotting: More thorough lysate clearing (higher centrifugation speeds, filtration)

  • For IHC/IF: Optimize fixation time and antigen retrieval conditions

• Reduce Primary Antibody Incubation Time: Shorter incubation at room temperature instead of overnight at 4°C can sometimes reduce non-specific binding.

• Use Highly Purified Secondary Antibodies: Cross-adsorbed secondary antibodies can minimize cross-reactivity.

• Test Alternative Antibody Clones: If available, try antibodies targeting different epitopes of TRMT6.

For persistent issues, consider comparing results with alternative detection methods or using genetic approaches (siRNA knockdown) to validate specificity.

How can researchers validate the specificity of TRMT6 antibodies in their experimental systems?

Validating antibody specificity is crucial for reliable research outcomes. For TRMT6 antibodies, consider these validation approaches:

• Genetic Validation:

  • siRNA/shRNA knockdown of TRMT6 should reduce or eliminate the specific signal

  • CRISPR/Cas9-mediated knockout provides more definitive validation

  • Overexpression of tagged TRMT6 should show signal co-localization

• Molecular Weight Verification:

  • The observed molecular weight should match the predicted size (calculated: 56 kDa, observed: 55-60 kDa)

  • Any unexpected bands should be investigated for potential isoforms or post-translational modifications

• Peptide Competition Assay:

  • Pre-incubation of the antibody with a specific blocking peptide should abolish specific binding

  • This approach has been successfully used with related antibodies like TRPM6

• Multi-application Concordance:

  • Consistent results across different applications (WB, IHC, IF) increase confidence in specificity

  • Discrepancies may indicate application-specific limitations

• Mass Spectrometry Verification:

  • Immunoprecipitation followed by LC-MS/MS can confirm the identity of the detected protein

  • This approach has been used in proteome-wide antibody validation approaches

What emerging techniques might enhance TRMT6 antibody applications in research?

Several emerging technologies hold promise for expanding TRMT6 antibody applications:

• Computational Antibody Structure Prediction: Recent advances in computational techniques and large language models have improved the ability to predict antibody structures, which could aid in developing more specific TRMT6 antibodies with enhanced performance characteristics .

• Proteome-Scale Antibody Arrays: Technologies like PETAL (Proteome Epitope Tag Antibody Library), which includes over 62,000 antibodies for proteome-scale antibody generation, could be leveraged to develop comprehensive antibody resources for studying TRMT6 and its interaction partners simultaneously .

• Super-Resolution Microscopy: These techniques could provide unprecedented insights into the subcellular localization and dynamics of TRMT6, particularly in relation to tRNA processing and modification activities.

• Multiplexed Protein Detection: Methods like Imaging Mass Cytometry or CODEX could allow researchers to simultaneously visualize TRMT6 along with dozens of other proteins in the same sample.

• In situ Protein Analysis: Emerging methods for analyzing proteins directly in intact tissues could provide spatial context for TRMT6 function that is lost in homogenized samples.

These advanced approaches could significantly enhance our understanding of TRMT6 biology beyond what is possible with current standard antibody applications.

How might TRMT6 antibodies contribute to understanding stem cell biology?

Recent research has revealed important roles for TRMT6 in stem cell function, particularly in hematopoietic stem cells (HSCs) . TRMT6 antibodies could contribute to this field in several ways:

• Lineage Tracing Studies: Using TRMT6 antibodies in combination with stem cell markers could help track changes in expression during differentiation and determine if TRMT6 levels correlate with stemness.

• Regulatory Network Analysis: Combining TRMT6 antibody-based detection with analysis of other factors in the tRNA modification pathway could reveal regulatory networks governing stem cell maintenance.

• Patient-Derived Sample Analysis: TRMT6 antibodies could be used to assess expression in patient-derived stem cells to determine if alterations correlate with disease states or treatment responses.

• Therapeutic Target Validation: As tRNA modification emerges as a potential therapeutic target, TRMT6 antibodies will be crucial for validating target engagement and efficacy in preclinical models.

• Developmental Biology: Tracking TRMT6 expression during embryonic development could provide insights into when and where tRNA modifications become critical for cellular differentiation and tissue formation.

This research direction is particularly promising given the recent findings linking TRMT6 to HSC maintenance and self-renewal through tRNA m1A modification mechanisms .